Powder: -20°C for 3 years | In solvent: -80°C for 1 year
UNC-CA359 is a highly potent inhibitor of the epidermal growth factor receptor (EGFR), demonstrating an IC50 value of 18 nM. With strong anti-tumor activity, UNC-CA359 holds significant potential for chordoma research [1].
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
25 mg | ¥ 10,600 | 6-8周 | ||
50 mg | ¥ 13,800 | 6-8周 | ||
100 mg | ¥ 17,500 | 6-8周 |
产品描述 | UNC-CA359 is a highly potent inhibitor of the epidermal growth factor receptor (EGFR), demonstrating an IC50 value of 18 nM. With strong anti-tumor activity, UNC-CA359 holds significant potential for chordoma research [1]. |
体外活性 | UNC-CA359 (compound 45) loses activity on U-CH1, leaves some activity on U-CH2, and maintains inhibition on EGFR, with IC 50 s of >100 μM, 35 μM, and 18 nM, respectively [1]. UNC-CA359 (1 nM-0.1 mM; 72 h) has activity against chordoma with IC 50 s of 1.2 μM (CH22), and 3.0 μM (U-CH12), respectively [1]. UNC-CA359 shows UNC-CA359 (compound 102) has three main collateral kinase targets, and shows high potency towards SLK/STK10 with a promising selectivity ratio (NAK over SLK/STK10) of 22, while the binding constant K i values are 3.4 nM (GAK), 0.33 μM (SLK), 0.075 μM (STK10), respectively [2]. GAK: cyclin G associated kinase; SLK: STE20-like serine/threonine-protein kinase; STK10: serine/threonine-protein kinase 10. Cell Cytotoxicity Assay [1] Cell Line: Chordoma cell lines: CH22, UM-Chor1, U-CH12 and U-CH7; WS1 Concentration: 1 nM-100 μM Incubation Time: 72 hours Result: Demonstrated good potential against chordoma cells, with IC 50 s of 1.2 μM (CH22), 3.0 μM (U-CH12), 60 μM (UM-Chor1), 74 μM (U-CH7), respectively. Showed no toxicity towards WS1 cell (IC 50 >100 μM). |
分子量 | 339.78 |
分子式 | C18H14ClN3O2 |
CAS No. | 2676156-05-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
UNC-CA359 2676156-05-9 Inhibitor inhibitor inhibit